EU approval for Bydureon despite US setbacks
This article was originally published in Scrip
Executive Summary
Lilly told Scrip it intends to commence reimbursement discussions with payers in individual companies as soon as possible following the decision by European regulators to grant marketing approval for Bydureon (exenatide), the product's first marketing approval worldwide.